InvestLog
CTOR Citius Oncology, Inc. logo

CTOR Citius Oncology, Inc.

Healthcare
$0.87+0.00%OpenMarket Cap: $80.7M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.38

P/S

13.92

EV/EBITDA

-1.85

DCF Value

$0.10

FCF Yield

-21.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

80.1%

Operating Margin

-775.6%

Net Margin

-757.6%

ROE

-99.5%

ROA

-42.2%

ROIC

-103.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 null$1.7M$-26.6M$—
Q1 null$3.9M$-5.5M$—
Q4 null$0.00$-5.0M$—
FY null$0.00$-24.8M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$6.00 - $6.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Maxim GroupBuy
2025-09-23

Trading Activity

Insider Trades

View All
Webb Caroldirector
SellTue Sep 23
Smith Robert Josephdirector
SellTue Sep 23
MCGRATH DENNIS Mdirector
SellTue Sep 23
Mazur Leonard Ldirector, officer: Chief Executive Officer
SellTue Sep 23
Mayersohn Joel Daviddirector
SellTue Sep 23

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

US

Exchange

—

Beta

3.58

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Peers

ACTU logoACTUAPLT logoAPLTFATE logoFATEFBRX logoFBRXLNSR logoLNSRMCRB logoMCRBOWLT logoOWLTSCLX logoSCLXSPRO logoSPROVOR logoVOR